(1,3)-β-D-glucan as a prognostic marker of treatment response in invasive candidiasis

Siraya Jaijakul, Jose A. Vazquez, Robert N. Swanson, Luis Ostrosky-Zeichner

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Background. (1,3)-β-D-glucan (BG) is a biomarker for invasive candidiasis (IC). The usefulness of BG level as a prognostic marker of treatment outcome is not well characterized. Methods. Two hundred fifty-seven patients with proven IC were enrolled in an anidulafungin study. Clinical and microbiological responses at the end of therapy were evaluated. Serial serum BG was measured. Correlation of initial and final BG levels with overall outcome was assessed in each patient. Results. Two hundred three patients had at least 2 BG levels and outcomes assessed. The majority of IC was caused by non-Candida albicans (53%) and found in the blood (84%). Overall, treatment success was 85%. In successfully treated patients, the mean ± SD initial and final BG were 573 ± 681 pg/mL and 499 ± 635 pg/mL (P = .03), respectively; while in treatment-failure patients, the levels were 1224 ± 1585 pg/mL and 1293 ± 1283 pg/mL (P = .29), respectively. A negative slope in BG levels correlated with a successful treatment outcome with a positive predictive value (PPV) of 90%, and a positive slope in BG levels correlated with treatment failure with a negative predictive value (NPV) of 90%. The cutoff value for initial BG <416 pg/mL has potential to predict treatment success with a PPV of 89%. Conclusions. A decrease in BG levels during therapy is associated with treatment success. An initial BG of <416 pg/mL has potential to predict successful treatment outcomes. Baseline and consecutive serum BG measurements may be useful as prognostic markers of treatment outcome in patients with IC receiving primarily echinocandin therapy.

Original languageEnglish (US)
Pages (from-to)521-526
Number of pages6
JournalClinical Infectious Diseases
Volume55
Issue number4
DOIs
StatePublished - Aug 15 2012

Fingerprint

Invasive Candidiasis
Treatment Failure
anidulafungin
Therapeutics
Echinocandins
Serum
polyglucosan
Biomarkers

ASJC Scopus subject areas

  • Infectious Diseases
  • Microbiology (medical)

Cite this

(1,3)-β-D-glucan as a prognostic marker of treatment response in invasive candidiasis. / Jaijakul, Siraya; Vazquez, Jose A.; Swanson, Robert N.; Ostrosky-Zeichner, Luis.

In: Clinical Infectious Diseases, Vol. 55, No. 4, 15.08.2012, p. 521-526.

Research output: Contribution to journalArticle

Jaijakul, Siraya ; Vazquez, Jose A. ; Swanson, Robert N. ; Ostrosky-Zeichner, Luis. / (1,3)-β-D-glucan as a prognostic marker of treatment response in invasive candidiasis. In: Clinical Infectious Diseases. 2012 ; Vol. 55, No. 4. pp. 521-526.
@article{9bb301da40d547e0a49163564fd74570,
title = "(1,3)-β-D-glucan as a prognostic marker of treatment response in invasive candidiasis",
abstract = "Background. (1,3)-β-D-glucan (BG) is a biomarker for invasive candidiasis (IC). The usefulness of BG level as a prognostic marker of treatment outcome is not well characterized. Methods. Two hundred fifty-seven patients with proven IC were enrolled in an anidulafungin study. Clinical and microbiological responses at the end of therapy were evaluated. Serial serum BG was measured. Correlation of initial and final BG levels with overall outcome was assessed in each patient. Results. Two hundred three patients had at least 2 BG levels and outcomes assessed. The majority of IC was caused by non-Candida albicans (53{\%}) and found in the blood (84{\%}). Overall, treatment success was 85{\%}. In successfully treated patients, the mean ± SD initial and final BG were 573 ± 681 pg/mL and 499 ± 635 pg/mL (P = .03), respectively; while in treatment-failure patients, the levels were 1224 ± 1585 pg/mL and 1293 ± 1283 pg/mL (P = .29), respectively. A negative slope in BG levels correlated with a successful treatment outcome with a positive predictive value (PPV) of 90{\%}, and a positive slope in BG levels correlated with treatment failure with a negative predictive value (NPV) of 90{\%}. The cutoff value for initial BG <416 pg/mL has potential to predict treatment success with a PPV of 89{\%}. Conclusions. A decrease in BG levels during therapy is associated with treatment success. An initial BG of <416 pg/mL has potential to predict successful treatment outcomes. Baseline and consecutive serum BG measurements may be useful as prognostic markers of treatment outcome in patients with IC receiving primarily echinocandin therapy.",
author = "Siraya Jaijakul and Vazquez, {Jose A.} and Swanson, {Robert N.} and Luis Ostrosky-Zeichner",
year = "2012",
month = "8",
day = "15",
doi = "10.1093/cid/cis456",
language = "English (US)",
volume = "55",
pages = "521--526",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - (1,3)-β-D-glucan as a prognostic marker of treatment response in invasive candidiasis

AU - Jaijakul, Siraya

AU - Vazquez, Jose A.

AU - Swanson, Robert N.

AU - Ostrosky-Zeichner, Luis

PY - 2012/8/15

Y1 - 2012/8/15

N2 - Background. (1,3)-β-D-glucan (BG) is a biomarker for invasive candidiasis (IC). The usefulness of BG level as a prognostic marker of treatment outcome is not well characterized. Methods. Two hundred fifty-seven patients with proven IC were enrolled in an anidulafungin study. Clinical and microbiological responses at the end of therapy were evaluated. Serial serum BG was measured. Correlation of initial and final BG levels with overall outcome was assessed in each patient. Results. Two hundred three patients had at least 2 BG levels and outcomes assessed. The majority of IC was caused by non-Candida albicans (53%) and found in the blood (84%). Overall, treatment success was 85%. In successfully treated patients, the mean ± SD initial and final BG were 573 ± 681 pg/mL and 499 ± 635 pg/mL (P = .03), respectively; while in treatment-failure patients, the levels were 1224 ± 1585 pg/mL and 1293 ± 1283 pg/mL (P = .29), respectively. A negative slope in BG levels correlated with a successful treatment outcome with a positive predictive value (PPV) of 90%, and a positive slope in BG levels correlated with treatment failure with a negative predictive value (NPV) of 90%. The cutoff value for initial BG <416 pg/mL has potential to predict treatment success with a PPV of 89%. Conclusions. A decrease in BG levels during therapy is associated with treatment success. An initial BG of <416 pg/mL has potential to predict successful treatment outcomes. Baseline and consecutive serum BG measurements may be useful as prognostic markers of treatment outcome in patients with IC receiving primarily echinocandin therapy.

AB - Background. (1,3)-β-D-glucan (BG) is a biomarker for invasive candidiasis (IC). The usefulness of BG level as a prognostic marker of treatment outcome is not well characterized. Methods. Two hundred fifty-seven patients with proven IC were enrolled in an anidulafungin study. Clinical and microbiological responses at the end of therapy were evaluated. Serial serum BG was measured. Correlation of initial and final BG levels with overall outcome was assessed in each patient. Results. Two hundred three patients had at least 2 BG levels and outcomes assessed. The majority of IC was caused by non-Candida albicans (53%) and found in the blood (84%). Overall, treatment success was 85%. In successfully treated patients, the mean ± SD initial and final BG were 573 ± 681 pg/mL and 499 ± 635 pg/mL (P = .03), respectively; while in treatment-failure patients, the levels were 1224 ± 1585 pg/mL and 1293 ± 1283 pg/mL (P = .29), respectively. A negative slope in BG levels correlated with a successful treatment outcome with a positive predictive value (PPV) of 90%, and a positive slope in BG levels correlated with treatment failure with a negative predictive value (NPV) of 90%. The cutoff value for initial BG <416 pg/mL has potential to predict treatment success with a PPV of 89%. Conclusions. A decrease in BG levels during therapy is associated with treatment success. An initial BG of <416 pg/mL has potential to predict successful treatment outcomes. Baseline and consecutive serum BG measurements may be useful as prognostic markers of treatment outcome in patients with IC receiving primarily echinocandin therapy.

UR - http://www.scopus.com/inward/record.url?scp=84864474053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864474053&partnerID=8YFLogxK

U2 - 10.1093/cid/cis456

DO - 10.1093/cid/cis456

M3 - Article

C2 - 22573851

AN - SCOPUS:84864474053

VL - 55

SP - 521

EP - 526

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 4

ER -